argenx SE (NASDAQ:ARGX) Short Interest Update

argenx SE (NASDAQ:ARGX) saw a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 1,780,000 shares, a decline of 10.6% from the September 30th total of 1,990,000 shares. Based on an average daily volume of 288,900 shares, the short-interest ratio is presently 6.2 days.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Wedbush raised their price target on shares of argenx from $519.00 to $560.00 and gave the company an “outperform” rating in a report on Friday, July 26th. Citigroup upped their price target on argenx from $512.00 to $635.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Evercore ISI raised their price objective on argenx from $478.00 to $533.00 and gave the stock an “outperform” rating in a research report on Friday, July 12th. Truist Financial upped their target price on argenx from $480.00 to $540.00 and gave the company a “buy” rating in a research report on Monday, July 22nd. Finally, Oppenheimer raised argenx from a “market perform” rating to an “outperform” rating and set a $546.00 price target for the company in a report on Tuesday, July 23rd. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $550.44.

Hedge Funds Weigh In On argenx

Large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its stake in shares of argenx by 49.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock worth $2,167,235,000 after acquiring an additional 1,830,651 shares in the last quarter. Janus Henderson Group PLC boosted its position in argenx by 24.8% during the first quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock worth $872,690,000 after purchasing an additional 439,889 shares in the last quarter. Avoro Capital Advisors LLC grew its holdings in argenx by 0.3% in the first quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company’s stock valued at $487,609,000 after purchasing an additional 3,900 shares during the period. Clearbridge Investments LLC increased its position in shares of argenx by 3.6% in the second quarter. Clearbridge Investments LLC now owns 617,466 shares of the company’s stock valued at $265,535,000 after buying an additional 21,189 shares in the last quarter. Finally, Sei Investments Co. raised its stake in shares of argenx by 15.2% during the 2nd quarter. Sei Investments Co. now owns 381,544 shares of the company’s stock worth $164,079,000 after buying an additional 50,477 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Stock Down 0.2 %

argenx stock opened at $551.71 on Thursday. The business’s 50-day moving average price is $536.03 and its 200 day moving average price is $462.82. The firm has a market cap of $32.79 billion, a price-to-earnings ratio of -97.48 and a beta of 0.63. argenx has a 52 week low of $327.73 and a 52 week high of $571.97.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.